Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piroxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piroxicam SCHEMBL13462 | 1.00 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL28536166 | 1.00 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL2680486 | 1.00 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL15741898 | 1.00 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL29352427 | 1.00 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL6759456 | 0.99 | KDM4E (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL6942519 | 0.99 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL5084571 | 0.99 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL8908556 | 0.99 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL27394226 | 0.99 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827723-B1 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ROCKHILL, ALVIN T. | 2023-11-28 | — | — | US | claimed |
| CN-114601930-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114404595-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-04-29 | — | — | CN | claimed |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-06 | — | — | US | disclosed |
| CN-118697700-A | Piroxicam-containing solid dispersion and preparation method thereof | 重庆医科大学 | 2024-09-27 | — | — | CN | disclosed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-114796100-B | Piroxicam gel emplastrum and preparation method thereof | 中山大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116322662-A | Compositions and methods for treating or preventing diseases associated with beta coronavirus infection | 森贾姆制药有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4096814-A1 | SYSTEM AND METHOD TO PRODUCE PARTICLES OF ORGANIC SUBSTANCES | Nanoform Finland Oyj (FI) | 2022-12-07 | — | — | EP | disclosed |
| CN-114796100-A | Piroxicam gel emplastrum and preparation method thereof | 中山大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-114601930-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114404595-A | Combination therapy of PD-1 signaling inhibitors | 国立大学法人京都大学 | 2022-04-29 | — | — | CN | disclosed |
| EP-3973957-A1 | METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA | Sen-Jam Pharmaceutical LLC (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3968971-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096240-A | Method for treating familial adenomatous polyposis | 癌症预防制药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | PTGS1 16/4885PTGS2 37/4885KDM4E 1850/4885 |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | JAK1, TNF, CYP4A11 | PTGS1 16/4885PTGS2 37/4885KDM4E 1850/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | PTGS1 16/4885PTGS2 37/4885KDM4E 1850/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | PTGS1 16/4885PTGS2 36/4885KDM4E 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.